Yumafron Capsule 1.5 mg (Rivastigmine Tartrate)

Adult dose

Dosage: Rivastigmine is administered orally twice daily, in the morning and evening, with meals. ○ Adults: 1. Treatment of symptoms of mild to moderate Alzheimer’s dementia The initial dose is 3 mg of rivastigmine per day. Increase the dose for each patient at intervals of at least 2 weeks to the highest tolerated dose or the maximum recommended dose of 12 mg per day. Since this medicine showed greater efficacy at doses of 6 mg per day and higher in clinical trials, a target dose range of 6~12 mg per day is recommended for most patients. Recommended dose titration Administer 1.5 mg per dose twice daily for at least 2 weeks. If well tolerated, the dose may be increased to 3 mg per dose twice daily. Subsequent increases may be made to 4.5 mg per dose twice daily and, if well tolerated, after at least 2 weeks, to 6 mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or decreased appetite) or weight loss are observed, one or more doses may be omitted. However, if adverse reactions or weight loss persist, reduce the daily dose to the previous dose that was well tolerated. 2. Treatment of symptoms of mild to moderate dementia associated with Parkinson’s disease In controlled clinical trials in patients with dementia associated with Parkinson’s disease, rivastigmine was administered at 3~12 mg per day, divided into 2 doses per day. (1.5~6 mg per dose, twice daily.) The initial dose is 1.5 mg per dose twice daily. Depending on the patient’s tolerability, subsequent doses may be increased sequentially at intervals of at least 4 weeks, first to 3 mg per dose twice daily, then to 4.5 mg per dose twice daily, and then to 6 mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or decreased appetite), weight gain, or extrapyramidal symptoms (e.g., tremor) are observed during treatment, omitting one or more doses may reduce these symptoms. If adverse reactions persist, the daily dose may be temporarily reduced to the previous well-tolerated dose, or discontinuation of treatment may be considered. 3. Maximum recommended dose Administer 6 mg per dose orally twice daily. 4. Resumption of treatment The frequency and severity of adverse reactions generally increase at higher doses. If treatment is interrupted for more than 3 days, restart at the lowest daily dose and titrate as described above. ○ Patients with hepatic or renal impairment: 1. Exposure is increased in patients with moderate renal impairment and mild to moderate hepatic impairment, and more adverse reactions may occur. Therefore, take particular care when titrating the dose according to individual tolerability. 2. Do not administer to patients with severe hepatic impairment, as no studies have been conducted in these patients.

Child dose

○ Children: This medicine has not been studied in children; therefore, its use in children is not recommended.

This medication should not be used in certain patients. For example, it should not be administered to patients who are allergic to the active ingredient or other components, those with severe liver dysfunction, or those who have experienced skin allergic reactions from previous use of the patch form of this medication. Patients with heart diseases, a history of peptic ulcers or duodenal ulcers, asthma or chronic obstructive pulmonary disease, urinary retention or seizures, and those with extrapyramidal symptoms should use this medication with caution. During treatment with this medication, gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea may frequently occur, especially during the dosage adjustment period. Neurological symptoms such as dizziness, headache, drowsiness, and tremor may also be present. For patients with dementia related to Parkinson's disease, this medication may exacerbate Parkinson's symptoms; hence, changes in symptoms should be monitored closely. This medication may interact with other cholinergic or anticholinergic medications, so special care is needed when co-administered. Additionally, this medication should be temporarily discontinued before the administration of anesthetics. Women who are pregnant or breastfeeding should consult a physician since the safety of this medication has not been adequately determined. Its use in children is not recommended. In case of overdose, symptoms such as nausea, vomiting, diarrhea, dizziness, bradycardia, and seizures may appear, and immediate medical attention should be sought. This medication must be stored out of reach of children and should not be transferred into another container.

• nausea
• vomiting
• urinary tract infection
• agitation
• confusion
• nightmares
• anxiety
• insomnia
• depression
• hallucinations

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 to 30 degrees Celsius.

Appearance

Yellow capsules containing white powder

Package unit

30 capsules/bottle, 100 capsules/bottle